venetoclax,quizartinib,decitabine
roche,abbvie,daiichi sankyo
['triplet', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'congrat']
i also found these data very impressive! 82% cr in r/r and 100%! in frontline triplet for flt3+aml. times are changing fast in the aml landscape. congrats dr. yilmaz! #eha2022 
Internal Medicine, Haematology and Oncology resident. Stem Cell Therapy Unit - University Hospital Augsburg. Passionate about AML, SCT and cellular therapies.